Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
Tóm tắt
Từ khóa
Tài liệu tham khảo
Balagula Y, Garbe C, Myskowski P, Hauschild A, Rapoport B, Boers-Doets CB, Lacouture ME (2011) Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 50:129–146
Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72(3–4):152–159
Somerfield M, Padberg J, Pfister D et al (2000) ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Classic Papers Curr Comments 4:881–886
Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6(10):803–812
Hassel JC, Kripp M, Al-Batran S, Hofheinz RD (2010) Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie 33(3):94–98
Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM Jr, Schaefer PL, Novotny PJ, Wender DB, Gross HM, Loprinzi CL (2010) Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer (in press)
Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, Mattar BI, Nikcevich DA, Novotny P, Sekulic A, Loprinzi CL (2010) Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist 15(9):1016–1022
Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113(4):847–853
Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, Halpern AC (2009) A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 61(4):614–620
Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28(8):1351–1357
Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25(34):5390–5396
Katzer K, Tietze J, Klein E, Heinemann V, Ruzicka T, Wollenberg A (2010) Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab—a report of 29 patients. Eur J Dermatol 20(1):82–84
Perez-Soler R, Zou Y, Li T, Tornos C, Ling Y (2006) Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin. J Clin Oncol ASCO Annual Meeting Proceedings part I, vol. 24, no. 18S (June 20 Supplement)
Radovics N, Kornek G, Thalhammer F, Weihsengruber F, Pietrzak C, Resch G, Petzer AL, Hauser I, Wogritsch C, Greil R (2010) Analysis of the effects of vitamin K1 cream on cetuximab-induced acne-like rash. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 28:15S (May 20 Supplement)
Bidoli P, Cortinovis DL, Colombo I, Crippa A, Cicchiello F, Villa F, Cazzaniga ME, Altomare G (2010) Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer. J Thorac Oncol 5(10):1662–1663
Vezzoli P, Marzano AV, Onida F, Alessi E, Galassi B, Tomirotti M, Berti E (2008) Cetuximab-induced acneiform eruption and the response to isotretinoin. Acta Derm Venereol 88(1):84–86
Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J (2005) Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 153(4):849–851
Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B (2007) A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 57(5):767–774
Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, Trancik RJ (2002) A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 47(3):377–385
Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD (2004) A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 50(4):541–553
Burtness B, Anadkat M, Basti S et al (2009) NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc 7(S1):s5–s21
Ocvirk J, Cencelj S (2010) Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. JEADV 24:453–459
Hoffmann R (2008) A 4-month, open-label study evaluating the efficacy of eflornithine 11.5% creamin the treatment of unwanted facial hair in women using TrichoScan. Eur J Dermatol 18(1):65–70
Jackson J, Caro JJ, Caro G, Garfield F, Huber F, Zhou W, Lin CS, Shander D, Schrode K, Eflornithine HCl Study Group (2007) The effect of eflornithine 13.9% cream on the bother and discomfort due tohirsutism. Int J Dermatol 46(9):976–981
Amin SP, Goldberg DJ (2006) Clinical comparison of four hair removal lasers and light sources. J Cosmet Laser Ther 8(2):65–68
Hamzavi I, Tan E, Shapiro J, Lui H (2007) A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. J Am Acad Dermatol 57(1):54–59
Smith SR, Piacquadio DJ, Beger B, Littler C (2006) Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. Dermatol Surg 32(10):1237–1243
Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at http://ctep.cancer.gov/forms/CTCAEv3.pdf
Campbell IR, Illingworth MH (1992) Can patients wash during radiotherapy to the breast or chest wall? A randomized controlled trial. Clin Oncol (R Coll Radiol) 4:78–82
Roy I, Fortin A, Larochelle M (2001) The impact of skin washing with water and soap during breast irradiation: a randomized study. Radiother Oncol 58:333–339
Salvo N, Barnes E, van Draanen J, Stacey E, Mitera G, Breen D, Giotis A, Czarnota G, Pang J, De Angelis C (2010) Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature. Curr Oncol 17(4):94–112
Miller RC, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Stoffel TJ, Haselow RE, Schaefer PL, Bearden JD 3rd, Atherton PJ, Loprinzi CL, Martenson JA (2010) Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. Int J Radiat Oncol Biol Phys 79:1460–1466
Elliott EA, Wright JR, Swann RS et al (2006) Phase III trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13. J Clin Oncol 24:2092–2097
Aygenc E, Celikkanat S, Kaymakci M et al (2004) Prophylactic effect of pentoxifylline on radiotherapy complications: a clinical study. Otolaryngol Head Neck Surg 130:351–356
Lin LC, Que J, Lin LK, Lin FC (2006) Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. Int J Radiat Oncol Biol Phys 65:745–750
Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425–1433
Segaert S, Tabernero J, Chosidow O et al (2005) The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 3:599–606
Roé E, García Muret MP, Marcuello E, Capdevila J, Pallarés C, Alomar A (2006) Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 55:429–437
Racca P, Fanchini L, Caliendo V et al (2008) Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an Oncologic/Dermatologic Cooperation. Clin Colorectal Cancer 7:48–54
Monroe EW, Bernstein DI, Fox RW et al (1992) Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. Arzneimittelforschung 42:1119–1121
Monroe EW (1992) Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther 14(1):17–21
Porzio G, Aielli F, Verna L, Porto C, Tudini M, Cannita K, Ficorella C (2006) Efficacy of pregabalin in the management of cetuximab-related itch. J Pain Symptom Manage 32:397–398
Goutos I, Eldardiri M, Khan AA, Dziewulski P, Richardson PM (2010) Comparative evaluation of antipruritic protocols in acute burns. The emerging value of gabapentin in the treatment of burns pruritus. J Burn Care Res 31(1):57–63
Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H (2004) Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 19(12):3137–3139
Vincenzi B, Tonini G, Santini D (2010) Aprepitant for erlotinib-induced pruritus. N Engl J Med 363:397–398
Bromm B, Scharein E, Darsow U, Ring J (1995) Effects of menthol and cold on histamine-induced itch and skin reactions in man. Neurosci Lett 187:157–160
Drake LA, Millikan LE (1995) The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group. Arch Dermatol 131(12):1403–1408
Shohrati M, Davoudi SM, Keshavarz S, Sadr B, Tajik A (2007) Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial. Cutan Ocul Toxicol 26(3):249–255
Pour-Reza-Gholi F, Nasrollahi A, Firouzan A, Nasli Esfahani E, Farrokhi F (2007) Low-dose doxepin for treatment of pruritus in patients on hemodialysis. Iran J Kidney Dis 1(1):34–37
Eschler DC, Klein PA (2010) An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus. J Drugs Dermatol 9(8):992–997
Khuntia D, Harris J, Bentzen SM et al (2008) Increased oral mucositis after IMRT versus non-IMRT when combined with cetuximab and cisplatin or docetaxel for head and neck cancer: preliminary results of RTOG 0234. Int J Radiat Oncol Biol Phys 72(1):S33
Motzer RJ, Amato R, Todd M et al (2003) Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21(1):99–101
Xiong HQ, Rosenberg A, LoBuglio A et al (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22(13):2610–2616
Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7):1201–1208
Reynolds NA, Wagstaff AJ (2004) Cetuximab—in the treatment of metastatic colorectal cancer. Drugs 64(1):109–118
Vermorken JB, Trigo J, Hitt R et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25(16):2171–2177
Belani CP, Schreeder MT, Steis RG et al (2008) Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer 113(9):2512–2517
Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Engl J Med 359(11):1116–1127
Thomas M (2005) Cetuximab: adverse event profile and recommendations for toxicitmanagement. Clin J Oncol Nurs 9(3):332–338
Lenz HJ (2006) Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology 20(5 Suppl 2):5–13
Keefe DM, Schubert MM, Elting LS, St S, Epstein JB, Raber-Drulacher JE et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucostis. Cancer 109(5):820–831
Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9):2026–2046
Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R (2007) Orofacial pain in cancer: part II: clinical perspectives and management. J Dent Res 86(6):506–518
Gorsky M, Epstein J, Raviv A, Yaniv R, Truelove E (2008) Topical minocycline for managing symptoms of recurrent aphthous stomatitis. Spec Care Dent 28(1):27–31
Gorsky M, Epstein JB, Sl R, Elishoov H, Yarom N (2007) Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study. Dermatol Online J 13(2):1
Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN (2009) Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer 10(2):106–111
Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW (2007) Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56(2):317–326
Ricciardi S, Tomao S, de Marinis F (2009) Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10(1):28–35
Saif MW, Kaley K, Lamb L, Pecerillo J, Hotchkiss S, Steven L, Brennan M, Penney R, Gillespie C, Shaib W (2010) Management of skin toxicities of anti-EGFR agents in patients with pancreatic cancer and other GI tumors by using electronic communication: effective and convenient. JOP 11(2):176–182
Gutzmer R, Werfel T, Kapp A, Elsner J (2006) Cutaneous side effects of EGF-receptor inhibition and their management. Hautarzt 57(6):509–513
Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulières D, Saltz L, Leyden J (2005) HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10(5):345–356
Wollenberg A, Kroth J, Hauschild A, Dirschka T (2010) Cutaneous side effects of EGFR inhibitors—appearance and management. Dtsch Med Wochenschr 135(4):149–154
Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA (2005) Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 23(1):165–174
Jennings MB, Alfieri D, Ward K, Lesczczynski C (1998) Comparison of salicylic acid and urea versus ammonium lactate for the treatment of foot xerosis. A randomized, double-blind, clinical study. J Am Podiatr Med Assoc 88(7):332–336
Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144(6):1169–1176
Becker A, van Wijk A, Smit EF, Postmus PE (2010) Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer. J Thorac Oncol 5(9):1477–1480
OSI Pharmaceuticals (2005) Tarceva package insert
ImClone Systems (2006) Erbitux package insert
Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, Besse B, Robert C (2009) Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 161(3):515–521
Hong SH, Wong CW, Privalsky ML (1998) Signaling by tyrosine kinases negatively regulates the interaction between transcription factors and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) corepressor. Mol Endocrinol 12:1161–1171
Baran R (1986) Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects. Clin Exp Dermatol 11:148–152
Bouscarat F, Bouchard C, Bouhour D (1998) Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir. N Engl J Med 338:1776–1777
Sassone LM, Fidel RA, Murad CF, Fidel SR, Hirata R Jr (2008) Antimicrobial activity of sodium hypochlorite and chlorhexidine by two different tests. Aust Endod J 34(1):19–24
Eames T, Grabein B, Kroth J, Wollenberg A (2010) Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol 24(8):958–960
Floersheim GL (1989) Treatment of brittle fingernails with biotin. Z Hautkr 64(1):41–48
Tosti A, Piraccini BM, Ghetti E, Colombo MD (2002) Topical steroids versus systemic antifungals in the treatment of chronic paronychia: an open, randomized double-blind and double dummy study. J Am Acad Dermatol 47(1):73–76
Wollina U (2001) Acute paronychia: comparative treatment with topical antibiotic alone or in combination with corticosteroid. J Eur Acad Dermatol Venereol 15(1):82–84
Rao A, Bunker C (2010) Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. Br J Dermatol 163(1):208
Rigopoulos D, Gregoriou S, Belyayeva E, Larios G, Ontochristopoulos G, Katsambas A (2009) Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. Br J Dermatol 160(4):858–860
Daniel CR 3rd, Daniel MP, Daniel CM, Sullivan S, Ellis G (1996) Chronic paronychia and onycholysis: a thirteen-year experience. Cutis 58:397–401
Rosenbaum D, Merenstein D, Meyer F (2002) Topical steroids more effective than antifungals for chronic paronychia. J Fam Pract 51:824
Roberts DT, Richardson MD, Dwyer PK, Donegan R (1992) Terbinafine in chronic paronychia and candida onychomycosis. J Derm Treat S1:39–42
Rutala WA, Weber DJ (1997) Uses of inorganic hypochlorite (bleach) in health-care facilities. Clin Microbiol Rev 10(4):597–610
Shu KY, Kindler HL, Medenica M, Lacouture M (2006) Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol 154(1):191–192
Wilhelmi BJ, Calianos TA II, Appelt EA, Ortiz ME, Heggers JP, Phillips LG (1999) Modified Dakin’s solution for cutaneous vibrio infections. Ann Plast Surg 43(4):386–389
Rutala WA, Cole EC, Thomann CA, Weber DJ (1998) Stability and bactericidal activity of chlorine solutions. Infect Control Hosp Epidemiol 19(5):323–327
Quitkin HM, Rosenwasser MP, Strauch RJ (2003) The efficacy of silver nitrate cauterization for pyogenic granuloma of the hand. J Hand Surg Am 28(3):435–438
Ghodsi SZ, Raziei M, Taheri A, Karami M, Mansoori P, Farnaghi F (2006) Comparison of cryotherapy and curettage for the treatment of pyogenic granuloma: a randomized trial. Br J Dermatol 154(4):671–675
Saltz L, Rubin MS, Hochster H et al (2001) Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor. Clin Cancer Res 7:3766s (abstract 559)
Bentzen SM, Trotti A (2007) Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 25(26):4096–4103
Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26(3):374–379
Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluropyrimidines. J Clin Oncol 24(30):4814–4921
Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22(1):77–85
Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA (2007) Phase II clinical trial of chemotherapy-naive patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 29(7):760–766
West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR (2006) Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 24(12):1807–1813
Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE (2005) Phase II trial of gefitinib 250 mg po daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11(23):8418–8424
Meropol NJ, Berlin J, Hecht JR et al (2003) Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22:256
Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22(16):3238–3247
Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 22(5):785–794
Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18:509–522
MASCC EGFR Inhibitor Skin Toxicity Tool (MESTT). Available at http://www.mascc.org/mc/page.do?sitePageId=98483
NCI Common Terminology Criteria for Adverse Events v4.03 (CTCAE). Available at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf